ARCHIMED Acquires Majority Stake in Germany's Zyto Group
January 12, 2021
ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.
- Buyers
- ARCHIMED (MED II fund)
- Targets
- Zyto group, Zytomed Systems GmbH, ZytoVision GmbH, 42 life sciences GmbH & Co. KG
- Sellers
- Founders and management
- Industry
- Medical Devices
- Location
- Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ARCHIMED Acquires BioVendor Group
March 11, 2025
Medical Devices
ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.
-
ARCHIMED Acquires Majority Stake in Title21 Health Solutions
July 12, 2022
Healthcare Services
ARCHIMED has acquired a majority stake in Phoenix-based Title21 Health Solutions through its MED III fund, with founders Lynn Fischer and Kent Kirimli retaining a significant minority. Title21 is an end-to-end software provider for cell and gene therapy labs; ARCHIMED plans to accelerate R&D, international expansion (Europe and Asia) and further digitization of the sector.
-
ARCHIMED (MED Platform I) Acquires Majority Stake in CARSO
December 16, 2021
Healthcare Services
Transatlantic healthcare private equity firm ARCHIMED, via its MED Platform I fund and in partnership with CAPZA Expansion and Siparex, has acquired a majority stake in Lyon-based CARSO, a leader in purity and analytical testing for pharma, healthcare, environmental and food sectors. The deal (debt provided by Tikehau Capital and several banks) will support CARSO's internationalization and service-range expansion as the group aims to more than double current annual revenues (above €200 million).
-
ARCHIMED Acquires Majority Stake in Cardioline
November 17, 2021
Medical Devices
Trans-Atlantic private equity firm ARCHIMED has acquired a majority stake in Cardioline, a Trento, Italy-based maker of cardiology devices and Europe's largest provider of cardiology-focused telemedicine. The investment, made through ARCHIMED's MED III Fund, will support Cardioline's product and software development, international expansion and potential add-on M&A while founders retain a significant minority stake and remain in management.
-
ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)
November 3, 2021
Biotechnology
Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.
-
ARCHIMED Acquires 75% Stake in ActiGraph
May 18, 2020
Medical Devices
ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.